---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-114220"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2025-09-11T23:59:59+00:00"
generated_at: "2026-05-17T06:54:53.101197+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# enGene Q3 net loss $28.9M; hits LEGEND enrollment target, RMAT designation

## Summary
- Cash and marketable securities $224.9M; net loss $28.9M ($0.57/share) vs $14.1M ($0.32/share) YoY.
- Achieved target enrollment of 100 patients in LEGEND pivotal cohort; data update expected 4Q 2025.
- Detalimogene granted FDA RMAT designation; BLA submission planned for 2H 2026.
- Operating expenses $29.9M, up from $16.8M; R&D costs increased $11M on LEGEND manufacturing and clinical costs.
- Board appointed Philip Astley-Sparke, William Grossman, Michael Heffernan; promoted Matthew Boyd, Jill Buck, Katherine Chan.

## SEC filing metadata
- accession: 0000950170-25-114220
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2025-09-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000095017025114220/0000950170-25-114220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000095017025114220/engn-20250911.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-114220
- JSON: https://secwatch.observer/filing/0000950170-25-114220.json
- Plain text: https://secwatch.observer/filing/0000950170-25-114220.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.